WBSI Guided Personalized Delivery of TTFields
Whole-Brain Spectroscopy Guided Personalized Mapping of Transducer Arrays for Glioblastoma Patients Receiving Tumor Treating Fields
Sponsor: Abramson Cancer Center at Penn Medicine
This NA trial investigates GBM and Glioma Glioblastoma Multiforme and is currently actively recruiting participants. Abramson Cancer Center at Penn Medicine leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Recruiting NA
-
Mar 2025 — Mar 2026 [monthly]
Recruiting NA
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Feb 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Apr 2023 — Feb 2024 [monthly]
Recruiting NA
-
Feb 2023 — Apr 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Feb 2023 [monthly]
Not Yet Recruiting NA
-
May 2022 — Sep 2022 [monthly]
Not Yet Recruiting NA
-
Nov 2021 — May 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Abramson Cancer Center at Penn Medicine
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- NovoCure Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .